CN121318878A - 基于“古德”缓冲液的阳离子脂质 - Google Patents

基于“古德”缓冲液的阳离子脂质

Info

Publication number
CN121318878A
CN121318878A CN202510407099.5A CN202510407099A CN121318878A CN 121318878 A CN121318878 A CN 121318878A CN 202510407099 A CN202510407099 A CN 202510407099A CN 121318878 A CN121318878 A CN 121318878A
Authority
CN
China
Prior art keywords
bis
ethyl
alkyl
amino
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510407099.5A
Other languages
English (en)
Chinese (zh)
Inventor
F·德罗萨
邓红凤
R·戈德曼
S·卡文
S·卡玛卡
R·达萨里
R·兰迪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translation Bio Co
Sanofi Aventis France
Original Assignee
Translation Bio Co
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP220100953A external-priority patent/AR125352A1/es
Priority claimed from TW111114318A external-priority patent/TW202309002A/zh
Application filed by Translation Bio Co, Sanofi Aventis France filed Critical Translation Bio Co
Priority to CN202510407099.5A priority Critical patent/CN121318878A/zh
Publication of CN121318878A publication Critical patent/CN121318878A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202510407099.5A 2022-04-13 2023-04-13 基于“古德”缓冲液的阳离子脂质 Pending CN121318878A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510407099.5A CN121318878A (zh) 2022-04-13 2023-04-13 基于“古德”缓冲液的阳离子脂质

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ARP220100953A AR125352A1 (es) 2020-02-24 2022-04-13 Lípidos catiónicos a base de tampones de good
TW111114318A TW202309002A (zh) 2021-04-15 2022-04-14 基於「古德」緩衝液的陽離子脂質
PCT/US2022/025067 WO2022221688A1 (en) 2021-04-15 2022-04-15 "good"buffer-based cationic lipids
EP23305491 2023-04-04
PCT/EP2023/059726 WO2023198857A1 (en) 2022-04-13 2023-04-13 "good" buffer-based cationic lipids
CN202510407099.5A CN121318878A (zh) 2022-04-13 2023-04-13 基于“古德”缓冲液的阳离子脂质
CN202380046217.3A CN121285547A (zh) 2022-04-13 2023-04-13 基于“古德”缓冲液的阳离子脂质

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202380046217.3A Division CN121285547A (zh) 2022-04-13 2023-04-13 基于“古德”缓冲液的阳离子脂质

Publications (1)

Publication Number Publication Date
CN121318878A true CN121318878A (zh) 2026-01-13

Family

ID=86226317

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510407099.5A Pending CN121318878A (zh) 2022-04-13 2023-04-13 基于“古德”缓冲液的阳离子脂质
CN202380046217.3A Pending CN121285547A (zh) 2022-04-13 2023-04-13 基于“古德”缓冲液的阳离子脂质

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202380046217.3A Pending CN121285547A (zh) 2022-04-13 2023-04-13 基于“古德”缓冲液的阳离子脂质

Country Status (5)

Country Link
US (1) US20250263385A1 (https=)
EP (1) EP4508039A1 (https=)
JP (1) JP2025512049A (https=)
CN (2) CN121318878A (https=)
WO (1) WO2023198857A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AU2017357758B2 (en) 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
US20220233444A1 (en) * 2019-04-22 2022-07-28 Translate Bio, Inc. Thioester cationic lipids
WO2020227085A1 (en) * 2019-05-03 2020-11-12 Translate Bio, Inc. Di-thioester cationic lipids
WO2020257611A1 (en) * 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
IL301536A (en) 2020-09-23 2023-05-01 Translate Bio Inc Cationic lipids based on piperazine
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
TW202309002A (zh) 2021-04-15 2023-03-01 美商轉譯生技公司 基於「古德」緩衝液的陽離子脂質

Also Published As

Publication number Publication date
EP4508039A1 (en) 2025-02-19
WO2023198857A1 (en) 2023-10-19
US20250263385A1 (en) 2025-08-21
JP2025512049A (ja) 2025-04-16
CN121285547A (zh) 2026-01-06
WO2023198857A9 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
JP7791182B2 (ja) ピペラジンベースのカチオン性脂質
CN115667207B (zh) 基于酚酸脂质的阳离子脂质
CN116507606B (zh) 基于tes的阳离子脂质
US20260021055A1 (en) Asymmetric Piperazine-Based Cationic Lipids
CN121419982A (zh) 用于核酸递送的基于二脱水己糖醇的可电离脂质
JP2026500541A (ja) ビス－エステル及びアミドカチオン性脂質
CN121318878A (zh) 基于“古德”缓冲液的阳离子脂质
CN121568920A (zh) 具有芳香族头基团的基于三(羟甲基)甲基甘氨酸和柠檬酸的阳离子脂质
CN121464146A (zh) 具有芳香族头基团的基于固醇的阳离子脂质
WO2025061967A1 (en) "good" buffer-based cationic lipids for nucleic acid delivery
CN121752576A (zh) 用于核酸递送的辅助脂质
US20240270707A1 (en) "Good" buffer-based cationic lipids
CN117136182A (zh) 基于“古德”缓冲液的阳离子脂质
US20230150921A1 (en) Phenolic acid lipid based cationic lipids
CN121358710A (zh) 基于三(羟甲基)甲基甘氨酸和柠檬酸的阳离子脂质
HK40099554A (en) Piperazine-based cationic lipids
HK40099554B (en) Piperazine-based cationic lipids

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination